Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2025.
All research outputs
#28,746,682
of 34,517,649 outputs
Outputs from Cancer (0008543X)
#18,264
of 19,194 outputs
Outputs of similar age
#93,575
of 98,660 outputs
Outputs of similar age from Cancer (0008543X)
#124
of 126 outputs
Altmetric has tracked 34,517,649 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,194 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 98,660 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 126 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
